256 related articles for article (PubMed ID: 31969329)
21. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
22. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.
Hrachova M; Nguyen ENT; Fu BD; Dandekar MJ; Kong XT; Cadena G; Hsu FPK; Billimek J; Taylor TH; Bota DA
Front Neurol; 2020; 11():373. PubMed ID: 32435228
[No Abstract] [Full Text] [Related]
23. Malignant meningioma mTOR mutated and precision medicine.
Villani V; Tanzilli A; Vidiri A; Giangaspero F; Ciliberto G; Olivi A; Pace A
Neurol Sci; 2023 Mar; 44(3):1073-1075. PubMed ID: 36567410
[TBL] [Abstract][Full Text] [Related]
24. Atypical and anaplastic meningiomas treated with bevacizumab.
Nayak L; Iwamoto FM; Rudnick JD; Norden AD; Lee EQ; Drappatz J; Omuro A; Kaley TJ
J Neurooncol; 2012 Aug; 109(1):187-93. PubMed ID: 22544653
[TBL] [Abstract][Full Text] [Related]
25. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
Chamberlain MC; Glantz MJ
Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
[TBL] [Abstract][Full Text] [Related]
26. Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
Karajannis MA; Mauguen A; Maloku E; Xu Q; Dunbar EM; Plotkin SR; Yaffee A; Wang S; Roland JT; Sen C; Placantonakis DG; Golfinos JG; Allen JC; Vitanza NA; Chiriboga LA; Schneider RJ; Deng J; Neubert TA; Goldberg JD; Zagzag D; Giancotti FG; Blakeley JO
Mol Cancer Ther; 2021 Sep; 20(9):1584-1591. PubMed ID: 34224367
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Lou E; Sumrall AL; Turner S; Peters KB; Desjardins A; Vredenburgh JJ; McLendon RE; Herndon JE; McSherry F; Norfleet J; Friedman HS; Reardon DA
J Neurooncol; 2012 Aug; 109(1):63-70. PubMed ID: 22535433
[TBL] [Abstract][Full Text] [Related]
28. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
Pinker B; Barciszewska AM
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
[TBL] [Abstract][Full Text] [Related]
29. Everolimus effectively blocks pulmonary metastases from meningioma.
Bertolini F; Pecchi A; Stefani A; Fontana A; Rossi G
Neuro Oncol; 2015 Sep; 17(9):1301-2. PubMed ID: 26293327
[No Abstract] [Full Text] [Related]
30. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: prognosis and identification by ¹¹¹Indium-octreotide imaging.
Alexandru D; Glantz MJ; Kim L; Chamberlain MC; Bota DA
Cancer; 2011 Oct; 117(19):4506-11. PubMed ID: 21446045
[TBL] [Abstract][Full Text] [Related]
31. VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
Decker T; Marschner N; Muendlein A; Welt A; Hagen V; Rauh J; Schröder H; Jaehnig P; Potthoff K; Lerchenmüller C
Breast Cancer Res Treat; 2019 Aug; 176(3):637-647. PubMed ID: 31115844
[TBL] [Abstract][Full Text] [Related]
32. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
33. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
34. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
35. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Norden AD; Raizer JJ; Abrey LE; Lamborn KR; Lassman AB; Chang SM; Yung WK; Gilbert MR; Fine HA; Mehta M; Deangelis LM; Cloughesy TF; Robins HI; Aldape K; Dancey J; Prados MD; Lieberman F; Wen PY
J Neurooncol; 2010 Jan; 96(2):211-7. PubMed ID: 19562255
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
[TBL] [Abstract][Full Text] [Related]
38. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
40. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
Zhang D; Way JS; Zhang X; Sergey M; Bergsneider M; Wang MB; Yong WH; Heaney AP
J Clin Endocrinol Metab; 2019 Jun; 104(6):1929-1936. PubMed ID: 30624667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
